Compare APPN & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | HROW |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | APPN | HROW |
|---|---|---|
| Price | $23.19 | $33.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $33.83 | ★ $71.14 |
| AVG Volume (30 Days) | 633.3K | ★ 992.4K |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $226,743,000.00 | N/A |
| Revenue This Year | $13.79 | $32.90 |
| Revenue Next Year | $10.56 | $48.52 |
| P/E Ratio | $1,199.50 | ★ N/A |
| Revenue Growth | ★ 28.29 | N/A |
| 52 Week Low | $21.77 | $20.85 |
| 52 Week High | $46.06 | $54.98 |
| Indicator | APPN | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 34.70 |
| Support Level | $21.77 | $32.55 |
| Resistance Level | $31.10 | $41.49 |
| Average True Range (ATR) | 0.95 | 1.54 |
| MACD | -0.16 | 0.21 |
| Stochastic Oscillator | 4.89 | 19.45 |
Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.